cisplatin
Showing 1 - 25 of 1,921
Pancreatic Adenocarcinoma, Homologous Recombination Deficiency Trial (Cisplatin)
Not yet recruiting
- Pancreatic Adenocarcinoma
- Homologous Recombination Deficiency
- Cisplatin
- (no location specified)
Oct 18, 2023
Chemo;Advanced Gastric Cancer;Cisplatin;Disulfiram Trial in Hangzhou (disulfiram and cisplatin, cisplatin)
Not yet recruiting
- Chemotherapy;Advanced Gastric Cancer;Cisplatin;Disulfiram
- disulfiram and cisplatin
- cisplatin
-
Hangzhou, Zhejiang, ChinaHangzhou first people's Hospital
Dec 26, 2022
Pancreatic Cancer Trial in Baltimore (Gemcitabine, Cisplatin, Pembrolizumab)
Not yet recruiting
- Pancreatic Cancer
- Gemcitabine
- +2 more
-
Baltimore, MarylandSKCCC Johns Hopkins
Aug 16, 2023
Cholangiocarcinoma Trial in Houston (Pembrolizumab, Gemcitabine, Cisplatin)
Not yet recruiting
- Cholangiocarcinoma
- Pembrolizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2023
Locally Advanced Cervical Cancer Trial in Xi'an (Zimberelimab, Albumin-bound Paclitaxel, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Zimberelimab
- +2 more
-
Xi'an, Shaanxi, ChinaHongxi Zhao
Sep 20, 2023
Neuroendocrine Carcinoma of the Bladder, Bladder Cancer Trial (Adebrelimab, Etoposide, Cisplatin)
Not yet recruiting
- Neuroendocrine Carcinoma of the Bladder
- Bladder Cancer
- Adebrelimab
- +3 more
- (no location specified)
Oct 14, 2023
Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)
Not yet recruiting
- Ovarian Cancer
- Malignant Neoplasm of Uterus
- Sacituzumab
- Cisplatin
-
New York, New YorkIcahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023
Epithelial Ovarian Cancer, Acute Kidney Injury Due to Circulatory Failure Trial (Sodium Sulfate, Hydration, Cisplatin)
Not yet recruiting
- Epithelial Ovarian Cancer
- Acute Kidney Injury Due to Circulatory Failure
- Sodium Sulfate
- +2 more
- (no location specified)
May 17, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)
Recruiting
- Nasopharyngeal Carcinoma
- Camrelizumab
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023
Malignant Pleural Mesothelioma, Mesothelioma Trial in Tampa (Cisplatin, Methotrexate, Gemcitabine)
Active, not recruiting
- Malignant Pleural Mesothelioma
- Mesothelioma
- Cisplatin
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 5, 2023
Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer Trial in Madison (Gemcitabine, Cisplatin, Zimberelimab)
Not yet recruiting
- Biliary Tract Carcinoma
- +2 more
- Gemcitabine
- +3 more
-
Madison, WisconsinUniversity of Wisconsin
Sep 15, 2023
Esophageal Squamous Cell Cancer Trial in Beijing (Toripalimab, Paclitaxel, Cisplatin)
Recruiting
- Esophageal Squamous Cell Cancer
- Toripalimab
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital / Peking University Cancer Hospital
Jan 30, 2023
Cholangiocarcinoma Non-resectable Trial in Chengdu (Candonilimab, Cisplatin, Gemcitabine)
Recruiting
- Cholangiocarcinoma Non-resectable
- Candonilimab
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Aug 4, 2023
Head Neck Cancer Trial in Singapore (carboplatin,, cisplatin, gemcitabine HCl)
Active, not recruiting
- Head and Neck Cancer
- carboplatin,
- +4 more
-
Singapore, SingaporeNational Cancer Centre - Singapore
Sep 27, 2022
Head Neck Cancer Trial in Billerica, Darmstadt (Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT))
Not yet recruiting
- Head and Neck Cancer
- Xevinapant
- +2 more
-
Billerica, Massachusetts
- +1 more
Sep 20, 2023
Nasopharyngeal Carcinoma, Nasopharyngeal Tumors, Nasopharyngeal Diseases Trial in Guangzhou (gemcitabine and cisplatin,
Recruiting
- Nasopharyngeal Carcinoma
- +3 more
- gemcitabine and cisplatin
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 4, 2022
Squamous Cell Carcinoma of the Head and Neck Trial in Strasbourg (Split Cisplatin, Cisplatin, Radiotherapy)
Completed
- Squamous Cell Carcinoma of the Head and Neck
- Split Cisplatin
- +2 more
-
Strasbourg, FranceCentre Paul Strauss
Mar 10, 2022
Nasopharyngeal Carcinoma, Recurrent or Metastatic Trial in Beijing (KL-A167, Gemcitabine, Cisplatin)
Not yet recruiting
- Nasopharyngeal Carcinoma
- Recurrent or Metastatic
- KL-A167
- +3 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Mar 23, 2022
Prostate Cancer Trial in Rochester (Cisplatin)
Recruiting
- Prostate Cancer
- Cisplatin
-
Rochester, New YorkWilmot Cancer Institute
Jun 7, 2022
Advanced Biliary Tract Cancer Trial in Guangzhou (Envofolimab, Lenvatinib, Gemcitabine)
Recruiting
- Advanced Biliary Tract Cancer
- Envofolimab
- +3 more
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Oct 11, 2022
Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),
Recruiting
- Oral Squamous Cell Carcinoma
- +3 more
- Toripalimab (anti-programmed death-1 inhibitor)
- +4 more
-
Shanghai, Shanghai, ChinaNinth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022
Nasopharyngeal Carcinoma, Nasopharyngeal Tumors, Nasopharyngeal Diseases Trial in Guangzhou (Nimotuzumab, Cisplatin)
Recruiting
- Nasopharyngeal Carcinoma
- +3 more
- Nimotuzumab
- Cisplatin
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 3, 2022
Head and Neck Squamous Cell Carcinoma Trial in Pittsburgh (Pembrolizumab, Cisplatin, IMRT)
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- Pembrolizumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 15, 2022
Triple Negative Breast Cancer Trial in Shanghai (Gemcitabine, Cisplatin)
Active, not recruiting
- Triple Negative Breast Cancer
- Gemcitabine
- Cisplatin
-
Shanghai, Shanghai, ChinaCancer Hospital/ Institute, Fudan University
Jul 19, 2022
Penile Cancer Trial in Guangzhou (Albumin-Bound Paclitaxel, Ifosfamide, Cisplatin)
Completed
- Penile Cancer
- Albumin-Bound Paclitaxel
- +4 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 8, 2022